This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Launched with small molecules licensed from Teva, 89bio (developing treatments for liver and metabolic diseases) concurrently raised $60mm through its Series A round. Founding investors OrbiMed Israel and OrbiMed US led the round and were joined by Longitude Capital, RA Capital Management, and Pontifax.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?